Largest biotech companies by cash on hand
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Amgen leads the 24 biotech companies ranked by cash on hand, at SAR 34.2B, ahead of BioNTech (SAR 31.9B) and Gilead Sciences (SAR 28.4B). Figures as of 18 Nov 2026, 21:28 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenSAR 34.2B
- Median
- SAR 1.6B
- Combined market value
- SAR 3.14T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Cash on hand ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | SAR 34.2B | SAR 900.6B | SAR 1,665.03 | 3.07% down | 34% up | ||
| 2 | BioNTechBNTX · Health Care | SAR 31.9B | SAR 77.4B | SAR 312.31 | 1.89% down | 16% down | ||
| 3 | Gilead SciencesGILD · Health Care | SAR 28.4B | SAR 786.2B | SAR 633.84 | 0.75% down | 33% up | ||
| 4 | argenxARGX · Health Care | SAR 13.1B | SAR 222B | SAR 3,530.63 | 0.66% down | 4% up | ||
| 5 | BiogenBIIB · Health Care | SAR 11.3B | SAR 139.4B | SAR 943.04 | 0.25% up | 49% up | ||
| 6 | ModernaMRNA · Health Care | SAR 9.7B | SAR 298.7B | SAR 738.16 | 4.84% down | 755% up | ||
| 7 | ImmunovantIMVT · Health Care | SAR 3.4B | SAR 25.7B | SAR 124.42 | 0.12% down | 43% up | ||
| 8 | QiagenQGEN · Health Care | SAR 3.1B | SAR 38.4B | SAR 185.90 | 0.38% down | 12% up | ||
| 9 | Neurocrine BiosciencesNBIX · Health Care | SAR 2.7B | SAR 61.8B | SAR 610.89 | 1.84% down | 20% up | ||
| 10 | RepligenRGEN · Health Care | SAR 2.1B | SAR 41.4B | SAR 647.69 | 6.47% up | 5% up | ||
| 11 | Krystal BiotechKRYS · Health Care | SAR 1.9B | SAR 35.1B | SAR 1,182.84 | 5.62% up | 46% up | ||
| 12 | ExelixisEXEL · Health Care | SAR 1.8B | SAR 62.5B | SAR 256.16 | 0.31% down | 63% up | ||
| 13 | Revolution MedicinesRVMD · Health Care | SAR 1.4B | SAR 129.7B | SAR 599.48 | 1.76% down | 131% up | ||
| 14 | Kymera TherapeuticsKYMR · Health Care | SAR 1.3B | SAR 38.8B | SAR 454.36 | 0.32% down | 87% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | SAR 1.3B | SAR 14.6B | SAR 150.75 | 0.10% up | 21% down | ||
| 16 | Scholar Rock HoldingSRRK · Health Care | SAR 1.2B | SAR 22B | SAR 180.05 | 6.48% up | 14% up | ||
| 17 | Bio-TechneTECH · Health Care | SAR 992.9M | SAR 42.9B | SAR 272.89 | 0.17% up | 26% up | ||
| 18 | Kodiak SciencesKOD · Health Care | SAR 787.2M | SAR 24B | SAR 366.89 | 1.04% up | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | SAR 686.6M | SAR 29.8B | SAR 436.43 | 3.88% up | 340% up | ||
| 20 | VaxcytePCVX · Health Care | SAR 652.5M | SAR 34.7B | SAR 219.51 | 1.48% down | 22% up | ||
| 21 | Halozyme TherapeuticsHALO · Health Care | SAR 502M | SAR 41B | SAR 359.35 | 0.18% down | 37% up | ||
| 22 | ImmunityBioIBRX · Health Care | SAR 331.3M | SAR 26.7B | SAR 25.13 | 7.03% up | 193% up | ||
| 23 | Adaptive BiotechnologiesADPT · Health Care | SAR 264.4M | SAR 17.3B | SAR 106.75 | 0.11% down | 88% up | ||
| 24 | CG OncologyCGON · Health Care | SAR 121.9M | SAR 26.8B | SAR 300.08 | 1.34% up | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Cash on hand is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7510 SAR).
Questions and answers
Which biotech companies rank first by cash on hand?
Amgen (SAR 34.2B), BioNTech (SAR 31.9B) and Gilead Sciences (SAR 28.4B) are the top three of the 24 biotech companies ranked by cash on hand as of 18 Nov 2026, 21:28 UTC.
How many biotech companies are in this ranking?
24 are ranked by cash on hand.
What are these biotech companies worth together?
The 24 biotech companies ranked by cash on hand have a combined market value of SAR 3.14T as of 18 Nov 2026, 21:28 UTC.
What does ranking by cash on hand measure?
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by cash on hand”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=cash-on-hand
Underlying data: Yahoo Finance; SEC EDGAR.